活检来源细胞周期进展评分对接受根治性前列腺切除术的美国国家综合癌症网络低危前列腺癌患者的预后价值:对治疗指导的意义
在三个机构接受根治性前列腺切除术的236例Gleason评分≤6前列腺癌男性中,80%(188/236)符合NCCN低危标准。低危队列中CCP评分低(<0)、中(0-1)、高(>1)组的5年无生化复发生存率分别为89.2%、80.4%、64.7%(P=0.03)。校正CAPRA评分后,CCP评分是低危队列(每单位评分HR 1.77,95%CI 1.21-2.58;P=0.003)和总队列(HR 1.41,95%CI 1.02-1.96;P=0.039)生化复发的独立预测因子。
要点
- 低危队列CCP低、中、高组5年无生化复发生存率分别为89.2%、80.4%、64.7%(P=0.03)。
- 低危队列校正CAPRA后CCP评分每单位HR 1.77(95%CI 1.21-2.58;P=0.003)。
- CCP评分或可改善主动监测候选资格评估并指导治疗选择。
核心结论
- 在NCCN定义的低危前列腺癌男性队列中,CCP评分改善了生化复发风险增高男性的临床风险分层,提示CCP评分可能改善主动监测候选资格评估并指导这些临床特征原本相似患者的优化治疗选择。
研究设计与样本
- 在三个机构(Martini Clinic、Durham Veterans Affairs Medical Center和Intermountain Healthcare)识别因Gleason评分≤6前列腺癌接受根治性前列腺切除术的男性。
- CCP评分来自诊断性活检(Durham Veterans Affairs Medical Center、Intermountain Healthcare)或模拟活检(Martini Clinic)。
- 主要结局为根治性前列腺切除术后的生化复发(前列腺特异性抗原≥0.2 ng/mL)。
- 采用Kaplan-Meier分析和多变量Cox比例风险模型在符合NCCN低危标准的亚组和总队列中评估CCP评分的预后价值。
主要发现
- 共识别236例男性,其中80%(188/236)符合NCCN低危标准。
- 低危队列中CCP评分低(<0)、中(0-1)、高(>1)组的5年无生化复发生存率分别为89.2%、80.4%、64.7%(P=0.03)。
- 总队列中CCP评分低(<0)、中(0-1)、高(>1)组的5年无生化复发生存率分别为85.9%、79.1%、63.1%(P=0.041)。
- 在校正临床和病理变量及前列腺癌风险评估(CAPRA)评分的多变量模型中,CCP评分是低危队列生化复发的独立预测因子(每单位评分HR 1.77,95%CI 1.21-2.58;P=0.003)。
- 在校正临床和病理变量及CAPRA评分的多变量模型中,CCP评分是总队列生化复发的独立预测因子(每单位评分HR 1.41,95%CI 1.02-1.96;P=0.039)。
临床怎么用
- 作者认为,CCP评分可能改善主动监测候选资格评估并指导这些临床特征原本相似患者的优化治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the prognostic utility of the cell cycle progression (CCP) score in men with National Comprehensive Cancer Network (NCCN)-defined low-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). PATIENTS AND METHODS: Men who underwent RP for Gleason score ≤6 PCa at three institutions (Martini Clinic [MC], Durham Veterans Affairs Medical Center [DVA] and Intermountain Healthcare [IH]) were identified. The CCP score was obtained from diagnostic (DVA, IH) or simulated biopsies (MC). The primary outcome was biochemical recurrence (BCR; prostate-specific antigen ≥0.2 ng/mL) after RP. The prognostic utility of the CCP score was assessed using Kaplan-Meier analysis and multivariable Cox proportional hazards models in the subset of men meeting NCCN low-risk criteria and in the overall cohort. RESULTS: Among the 236 men identified, 80% (188/236) met the NCCN low-risk criteria. Five-year BCR-free survival for the low (<0), intermediate (0-1) and high (>1) CCP score groups was 89.2%, 80.4%, 64.7%, respectively, in the low-risk cohort (P = 0.03), and 85.9%, 79.1%, 63.1%, respectively, in the overall cohort (P = 0.041). In multivariable models adjusting for clinical and pathological variables with the Cancer of the Prostate Risk Assessment (CAPRA) score, the CCP score was an independent predictor of BCR in the low-risk (hazard ratio [HR] 1.77 per unit score, 95% confidence interval [CI] 1.21, 2.58; P = 0.003) and overall cohorts (HR 1.41 per unit score, 95% CI 1.02, 1.96; P = 0.039). CONCLUSION: In a cohort of men with NCCN-defined low-risk PCa, the CCP score improved clinical risk stratification of men who were at increased risk of BCR, which suggests the CCP score could improve the assessment of candidacy for active surveillance and guide optimum treatment selection in these patients with otherwise similar clinical characteristics.
引用
- Tosoian JJ, Chappidi MR, Bishoff JT, et al. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. BJU Int. 2017. PMID: 28481440. doi:10.1111/bju.13911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。